|Massachusetts Institute of Technology - Sloan School of Management, MSc||1995|
|Management and Marketing|
|Ben-Gurion University of the Negev, BSc||1993|
|Chemical Engineering and Biotechnology|
Ittai Harel is a veteran of the life sciences industry. He has fifteen years of experience in this field covering a wide range of activities, from basic business and technology development to corporate executive management, in areas such as pharmaceutical development, drug delivery, medical devices and diagnostics.
Before joining Pitango, Ittai was Director of Corporate Development at Nektar Therapeutics (NASDAQ: NKTR) where he was responsible for strategic planning, in-licensing and M&A activities. Prior to his period with Nektar, Ittai held various management positions at large companies both in Israel and in the U.S. including IDEXX Laboratories (NASDAQ: IDXX) and IDGene Pharmaceuticals.
Ittai has a B.Sc. in Chemical Engineering and Biotechnology from Ben Gurion University, as well as an MBA from the MIT Sloan School of Management.
Ittai serves on the Board of Directors of Valeritas, EarlySense, Inotek Pharmaceuticals Corporation, B.P.T. Bio Pure Technology and LifeBond